Can a blood vessel drug save kidneys in scleroderma crisis?
NCT ID NCT01241383
First seen May 12, 2026 · Last updated Jun 19, 2026 · Updated 7 times
Summary
This study tested a drug called bosentan in 16 adults with scleroderma who had a serious kidney complication called scleroderma renal crisis. The goal was to see if bosentan could help protect kidney function and improve survival over 6 months to a year. The drug works by blocking a substance that narrows blood vessels, which may reduce kidney damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLERODERMA RENAL CRISIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pôle de médecine interne Centre de référence Maladies rares Groupe I Maladies systémiques et maladies auto-immunes rares en particulier Vascularites nécrosantes et les sclérodermies - Hôpital Cochin
Paris, 75014, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.